Nuvalent, Inc.
NASDAQ:NUVLBiotechnology
-$0.03 today
- Market cap
- $9.13B
- Beta
- 1.15
- P/E (TTM)
- -21.6
- EPS (TTM)
- -$5.72
Volume 0.00M
Average 1.91M
NUVL Sales of Investments
Cash received from selling or redeeming investments.
Nuvalent, Inc.NASDAQ: NUVL
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments dips below year-ago levels
Q1 FY2026 sales of investments of $181.55M fell 40.0% year over year, behind the +19.9% change in trailing-twelve-month sales of investments. Sequentially, it rose 11.3% from the prior quarter. Over 3 fiscal years it compounded at +66.5% a year.
Context
- Sales of investments increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -40.0% toward the trailing-twelve-month pace of +19.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 933.69M USD
- Year-over-year change
- +106.8%
- 4-year CAGR
- +450.7%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 933.69M | +106.8% |
| FY2024 | 2024-12-31 | 451.45M | +42.9% |
| FY2023 | 2023-12-31 | 315.96M | +56.2% |
| FY2022 | 2022-12-31 | 202.25M | +19826.2% |
| FY2021 | 2021-12-31 | 1.02M | — |
Sales of Investments vs competitors
How NUVL compares with its peers on the latest reported figures
- Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +19.9% is the 3rd highest of 7, against a peer median of +5.7%.
- Over three fiscal years its annual growth of +66.5% compares with a peer median of +28.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $2.83B USD | +92.5% | +183.0% | 60.0% | |
| LTM Jun 2026 | $1.96B USD | +26.8% | +110.4% | — | |
| LTM Sep 2026 | $1.12B USD | +3.3% | -5.4% | 4449.2% | |
| LTM Jun 2026 | $1.04B USD | +8.1% | +22.4% | 1460.6% | |
| LTM Mar 2026 | $812.64M USD | +19.9% | +66.5% | — | |
| LTM Sep 2026 | $695.23M USD | +0.8% | +28.6% | 154.2% | |
| LTM Sep 2026 | $283.78M USD | -1.6% | -3.9% | 101.1% | |
| FY2025 | €480.27K EUR | — | +30.1% | — | |
| LTM Jun 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding NUVL) | — | +5.7% | +28.6% | 127.6% | |
Competitors are the stored peer set for NUVL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (46.34M) | (81.85M) | (126.22M) | (260.76M) | (425.38M) |
| Depreciation & Amortization | 215K | (373K) | 0 | 0 | 0 |
| Deferred Income Tax | (215K) | (5.74M) | 0 | 0 | 0 |
| Stock-Based Compensation | 3.55M | 10.33M | 25.56M | 60.58M | 86.5M |
| Change in Working Capital | 1.94M | 6.93M | 11.03M | 11.84M | 19.21M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.64M | 4.21M | 2.17M | (4.05M) | 24.6M |
| Other Working Capital | 300K | 2.72M | 8.86M | 15.89M | (5.39M) |
| Other Non-Cash Items | 846K | 5.74M | (10.11M) | 3.27M | 44.46M |
| Operating Cash Flow | (40M) | (64.97M) | (99.74M) | (185.06M) | (275.21M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (221.04M) | (212.92M) | (459.49M) | (1.02B) | (1.06B) |
| Sales of Investments | 1.02M | 202.25M | 315.96M | 451.45M | 933.69M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (220.03M) | (10.67M) | (143.53M) | (573.51M) | (124.08M) |
| Debt Repayment | 284K | 0 | 0 | 0 | 0 |
| Common Stock Issued | 177.27M | 248.63M | 324.3M | 569.99M | 515.34M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.98M) | 286K | 12.55M | (1.11M) | 0 |
| Financing Cash Flow | 318.22M | 248.92M | 336.85M | 568.88M | 515.34M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 58.19M | 173.28M | 93.58M | (189.7M) | 116.05M |
| Free Cash Flow | (40M) | (64.97M) | (99.74M) | (185.06M) | (275.21M) |
Nuvalent, Inc.
NASDAQ:NUVL
Intrinsic Alpha fair value
Locked
Current Price
$123.96
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.